Bacteria Clinical Development Immune Response Regulation 
pharmaphorum
DECEMBER 4, 2020
Subject to approval from regulators the vaccine specialist said it plans the trial known as VLA15-221 as a randomised, observer-blind phase 2 study including around 600 healthy people aged 5-65 years of age. OspA is one of the most dominant surface proteins expressed by the bacteria when present in the ticks that spread the disease.
The Pharma Data
OCTOBER 19, 2020
Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. among adults 65 years of age or older.
The Pharma Data
DECEMBER 15, 2020
The human monoclonal antibody targets specific immune plasma cells. The researchers regulated the abnormal immunological memory processes found in these patients. Treatment induced sustainable clinical responses and reduced systemic inflammation. Daratumumab already is approved for the treatment of multiple myeloma.
Expert insights. Personalized for you.
119 
Let's personalize your content